Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical hyperthermia with a new device: the current sheet applicator

B R Leigh1, B Stea, J R Cassady

  • 1Department of Radiation Oncology, University of Arizona Health Sciences Center, Tucson 85724.

International Journal of Radiation Oncology, Biology, Physics
|November 15, 1994
PubMed
Summary

The novel current sheet applicator (CSA) effectively heats superficial tumors to therapeutic temperatures. Combined with radiotherapy, this microwave hyperthermia device shows excellent response rates and minimal toxicity for cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?

Journal of thrombosis and haemostasis : JTH·2012
Same author

Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women.

European journal of cancer care·2009
Same author

Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.

British journal of cancer·2006
Same author

Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation.

Journal of chemotherapy (Florence, Italy)·2005
Same author

Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

Limb volume reduction after physical treatment by compression and/or massage in a rodent model of peripheral lymphedema.

Lymphology·2002

Area of Science:

  • Oncology
  • Medical Physics
  • Biomedical Engineering

Background:

  • Microwave hyperthermia offers a promising adjunct to radiotherapy for cancer treatment.
  • Existing microwave applicators have limitations in size and heating area efficiency.
  • The current sheet applicator (CSA) presents a novel design with improved physical characteristics for targeted heating.

Purpose of the Study:

  • To evaluate the clinical efficacy of the current sheet applicator (CSA) for heating superficial malignant tumors.
  • To assess the feasibility of using CSA in arrays for larger surface areas.
  • To determine the therapeutic potential of CSA in combination with radiotherapy.

Main Methods:

  • Nineteen patients with superficial malignant tumors received hyperthermia using one to four CSAs.

Related Experiment Videos

  • Treatments aimed to reach a minimum tumor temperature of 42.5°C for 30 or 60 minutes.
  • Intratumoral temperatures were monitored using fiberoptic thermometry probes.
  • Concurrent fractionated radiation therapy was administered to all patients.

    • Main Results:

    • Mean tumor temperatures achieved were above therapeutic thresholds (average 42.2°C).
    • An overall response rate of 96% was observed across all assessable fields.
    • Tumor progression was minimal, with only three cases progressing during a median 6-month follow-up.
    • Treatment-related side effects were generally mild and self-limiting.

    Conclusions:

    • The current sheet applicator (CSA) is a viable new microwave hyperthermia device for superficial tumors.
    • CSA effectively heats tumors to therapeutic temperatures, demonstrating clinical efficacy.
    • Combining CSA with radiotherapy yields excellent response rates and acceptable toxicity profiles.